Currently, ADH1 patients receive treatment with conventional medication, such as calcium and vitamin D. But this treatment should be reserved due to the risk of hypercalciuria and severe complications such as nephrocalcinosis, nephrolithiasis and renal impairment.[13] Therefore, hydrochlorothiazide (0.5–2.0 mg/kg/day) should be administered alongside, leading to the increased reabsorption of calcium in the renal tubules. This evidence concerns the gene ADH1A and nephrolithiasis.